Case study

Case Study Long-Term Oncology Home Country Treatment Cost Optimization

Transforming Long-Term Oncology Care
Through Home Country Treatment

Prospera Global | How Prospera Global Delivered Seamless Cross-Border Cancer Care While Driving Significant Cost Optimization for the Insurer

Diagnosis: Relapsed Ewing's Sarcoma (WHO CNS Grade 4) Treating Hospital: Kasturba Hospital Manipal Treatment Duration: December 2023 – March 2026 Case Type: Long-Term Oncology & International Treatment Coordination

Executive Summary

Managing complex oncology cases requires far more than approvals and hospitalization coordination. It demands continuity of care, clinical oversight, emotional support, financial governance, and the ability to coordinate multiple stakeholders over an extended period of time.

Prospera Global successfully managed a highly complex Relapsed Ewing's Sarcoma oncology case over a treatment duration spanning approximately two and a half years.

Through its Home Country Treatment initiative, Prospera Global enabled the member to continue residing in the UAE while seamlessly undergoing advanced cancer treatment in India with structured travel coordination, uninterrupted treatment planning, and end-to-end insurance management support.

The case involved:

Multiple surgeries
Long-duration chemotherapy
Radiotherapy
Targeted oncology therapy
Continuous hospitalization support
Multi-stage approvals and claims coordination
Long-term treatment monitoring across disease recurrences

Despite the complexity and prolonged nature of the treatment, Prospera Global ensured uninterrupted access to advanced oncology care while helping facilitate an estimated 60%–75% reduction in overall treatment costs compared to high-cost international markets.

The Challenge

The patient was diagnosed with Relapsed Ewing's Sarcoma involving the lumbar spine region — a rare and aggressive malignancy requiring highly specialized multidisciplinary oncology care.

The complexity of the case significantly increased due to:

Multiple disease recurrences
Need for repeat spinal surgery
Continuous chemotherapy cycles
Radiotherapy and targeted therapy
Long-term hospitalization support
Frequent insurance approvals
Ongoing treatment adaptation based on disease progression

Unlike standard medical coordination cases, this was not a one-time admission management exercise. The case required sustained clinical and operational oversight across multiple years, treatment phases, and recurrence episodes.

What Prospera Global Did Differently

Managed the Complete Oncology Journey — Not Just Hospitalization

Prospera Global went beyond conventional insurance coordination by managing the member's complete oncology treatment lifecycle, including:

Treatment planning support
Hospital coordination
Insurance approvals
GOP management
Admission coordination
Claims documentation
Cost optimization
Follow-up continuity
Discharge coordination
Long-term treatment monitoring

This ensured the patient and insurer experienced a single coordinated ecosystem instead of fragmented healthcare interactions.

Facilitated Seamless Home Country Treatment & Travel While the Member Continued Living Comfortably in the UAE

One of the most impactful elements of this case was Prospera Global's ability to operationalize a practical and patient-friendly Home Country Treatment model.

While the member residing in the UAE, Prospera Global coordinated:

Planned treatment travel to India
Admission scheduling aligned with treatment cycles
Advance approvals before travel
Coordination with treating oncologists
Post-treatment discharge planning
Return travel support
Continuity of follow-up care

This significantly reduced the emotional and financial burden typically associated with prolonged international cancer treatment.

The member was able to undertake regular and hassle-free travel for treatment while continuing life in the UAE with dignity, comfort, and continuity.

Maintained Treatment Continuity During Multiple Recurrences

Managing oncology recurrence is operationally demanding for insurers and emotionally exhausting for patients.

Prospera Global ensured continuity during every stage of disease progression, including:

Re-surgery coordination
Radiotherapy scheduling
Targeted therapy approvals
Chemotherapy cycle management
Continuous hospitalization support
Clinical communication between stakeholders

Even during advanced disease progression, the treatment plan was continuously adapted to optimize outcomes and maintain uninterrupted access to care.

Clinical Journey Overview

Initial Surgical Intervention (2023)

The patient underwent:

L4 and partial L3 laminectomy with durotomy and excision surgery
Baseline PET imaging confirming no metastasis

Intensive Chemotherapy Phase

The patient successfully completed:

17 cycles of VAC/IE chemotherapy by November 2024

Initial response showed positive metabolic improvement.

Disease Recurrence & Advanced Oncology Support

Following recurrence identified in January 2025, Prospera Global coordinated:

Repeat surgery
Local radiotherapy
Palliative radiotherapy
Targeted therapy with Cabozantinib
IV supportive oncology treatment

Advanced Chemotherapy Management (2026)

Prospera Global further coordinated hospitalization and approvals for:

Topotecan + Cyclophosphamide chemotherapy
Multi-day admission management
Pegfilgrastim supportive therapy
Continuous inpatient monitoring

The patient tolerated treatment well and was discharged in stable condition with ongoing follow-up planning.

Financial Impact & Cost Containment

Through strategic treatment coordination in India and continuous insurer engagement, Prospera Global facilitated substantial cost savings while maintaining access to advanced oncology care.

Estimated Savings Achieved

USD 180,000 – 350,000

60%–75% reduction in oncology treatment costs

Treatment Component	Approx. India Cost	Approx. International Cost
Multi-cycle Chemotherapy	INR 12–18 Lakhs	USD 120,000–180,000
Major Surgeries & Recovery	INR 6–10 Lakhs	USD 60,000–100,000
Radiotherapy & Targeted Therapy	INR 8–15 Lakhs	USD 80,000–150,000
Ongoing Oncology Monitoring	INR 4–7 Lakhs	USD 40,000–70,000
Estimated Overall Value Managed	INR 30–50 Lakhs	USD 300,000–500,000

Value Delivered Beyond Cost Savings

Beyond financial optimization, the case demonstrated the operational and clinical advantages of Prospera Global's Home Country Treatment framework:

Faster treatment approvals
Reduced administrative burden on insurer
Better treatment continuity
Structured oncology coordination
Enhanced patient experience
Access to advanced oncology protocols
Centralized communication and governance
Long-term case monitoring

Outcome

Despite multiple recurrences and prolonged treatment requirements over approximately 2.5 years, the patient continued receiving uninterrupted advanced oncology care with full coordination support from Prospera Global.

This case stands as a strong example of how structured Home Country Treatment programs can successfully combine:

Clinical excellence
Patient-centric coordination
Long-term continuity of care
International treatment management
Sustainable healthcare cost optimization for insurers, TPAs, and policyholders alike

Case Details

DiagnosisRelapsed Ewing's Sarcoma (WHO CNS Grade 4)

Treating HospitalKasturba Hospital Manipal

Treatment DurationDecember 2023 – March 2026

Case TypeLong-Term Oncology & International Treatment Coordination

Member LocationUAE (Resident)

Treatment LocationIndia

75%

Reduction in Treatment Costs

India Treatment ValueINR 30–50 Lakhs

Equivalent InternationalUSD 300K–500K

Approx. SavingsUSD 180K–350K

⚠ The Challenge

🧬Rare and aggressive malignancy — lumbar spine involvement

🔁Multiple disease recurrences

🩺Repeat spinal surgery required

💊Continuous chemotherapy cycles

✈️Cross-border treatment logistics from UAE to India

📋Frequent multi-stage insurance approvals

Outcomes Achieved

✓60%–75% reduction in treatment costs

✓Approx. USD 180,000–350,000 savings

✓Uninterrupted care across 2.5 years

✓Seamless Home Country Treatment model

✓Continuity maintained through multiple recurrences

✓Reduced administrative burden on insurer

✓Access to advanced oncology protocols

✓Patient discharged in stable condition